Effectiveness of Laying-on-of-hands for Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseDeathPain Crisis RecurrentAnemiaInfection
- Interventions
- Behavioral: laying-on-of-hands
- Registration Number
- NCT01518218
- Lead Sponsor
- MOA Health Science Foundation
- Brief Summary
The objective of this study is to evaluate the effectiveness of 1-year administration of laying-on-of-hands on the morbidity and mortality of patients with sickle cell disease in Africa.
- Detailed Description
Patients with sickle cell disease (SCD) have a high risk of premature death in Africa, mainly due to insufficient medical services. SCD patients often visit emergency department and need hospitalization when they suffer from severe pain; however, they manage most of painful episodes at home. Appropriate pain management at home is, therefore, crucial to improve their clinical course and quality of life. Laying-on-of-hands may be a good candidate for home care management, because family member(s) can become a practitioner of laying-on-of-hands without difficulty and administer it to their loved one as an initial treatment whenever necessary. There are no reports concerning the effectiveness of laying-on-of-hands for the outcomes of SCD patients, as far as we have investigated.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- patients with symptoms associated with sickle cell disease
- those able to receive laying-on-of-hands every weekday for 1 year
- those able to receive conventional medical treatment whenever necessary
- those able to receive blood test at the beginning, after 6 month and after 1 year
- those who wish to use other complementary and alternative therapies along with laying-on-of-hands
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description laying-on-of-hands laying-on-of-hands Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
- Primary Outcome Measures
Name Time Method disease-related episodes and mortality 3 years and 9 months
- Secondary Outcome Measures
Name Time Method blood data 1 year
Trial Locations
- Locations (1)
The national medical center for sickle cell disease
🇨🇩Kinshasa, Congo, The Democratic Republic of the